Amazon to Expand Drone Delivery to 500 U.S. Locations 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Alibaba Shares Fall as AI Spending Hits Profit 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Add as a preferred source on Google
AUSTIN, Texas, May 03, 2018 -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter ended March 31, 2018 financial results on Monday, May 14, 2018, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
| Monday, May 14th @ 4:30pm Eastern Time | |||
| Domestic: | 800-239-9838 | ||
| International: | 323-794-2551 | ||
| Conference ID: | 5200441 | ||
| Webcast: | http://public.viavid.com/index.php?id=129615 | ||
| Replays, Available through May 28: | |||
| Domestic: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Replay PIN: | 5200441 | ||
About Vermillion
Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. Vermillion, Inc.’s tests are intended to characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-535-7742
[email protected]
